India's Piramal Pharma gains on Q2 profit surge
** Shares of Piramal Pharma PIRM.NS rise 6.5% to 233
rupees
** Co posted a near five-fold surge in Q2 consol net profit
to 225.9 mln rupees (~$3 million)
** Revenue in core contract development and manufacturing
organisation segment jumps 24%
** More than 12 mln shares change hands, 1.5x its 30-day avg
** Five analysts covering the stock on avg have a "buy"
rating; median PT is 260 rupees - LSEG data
** Stock up 68% so far this year
($1 = 84.0650 Indian rupees)
(Reporting by Ashna Teresa Britto in Bengaluru)
((AshnaTeresa.Britto@thomsonreuters.com ; ( +91 8078332441))
Recent news on Piramal Pharma (Mumbai)
See all newsBrief: Piramal Pharma (Mumbai) Says Commercial Arrangement With Bayer Pharmaceuticals To Expire On December 31, 2026
Brief: Piramal Pharma (Mumbai) Says Tax Authority Confirms Demand Of 40.6 Million Rupees And Imposes Equivalent Penalty
India's Piramal Pharma falls after US FDA observations at UK facility
Brief: Piramal Pharma Says US FDA Issues Form-483 With 7 Observations To Morpeth UK Facility
Brief: Piramal Pharma Approves Exercise Of Call Option For Acquisition Of Additional 41% Equity In Yapan Bio